Search

Search Constraints

You searched for: Author/Creator Steinberg, Michael L.

Search Results

1. 97: Four-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated with Ablative Therapies: The Sprat Analysis. (October 2021)

2. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. (May 2018)

3. Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial. (May 2022)

4. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. (March 2023)

5. Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. (20th July 2021)

6. Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. (August 2018)

8. Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. (January 2021)

9. Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. (February 2022)

10. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose–volume histogram using ensemble machine learning. (July 2020)